Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

China - October 28, 2024 Danish pharma's success exemplifies China's growing global appeal (Voice_over) For the past three decades, Danish pharmaceutical company Novo Nordisk has been steadily ...

He has a lot of experience doing the hard work ... Carrasco worked for companies like Johnson & Johnson, Novartis and Novo Nordisk, major players in the pharmaceuticals industry.

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar ... "The budget hit here is frightening for a lot of governments and private ...

And Novo Nordisk is asking the U.S. Food and Drug Administration (FDA) to bar compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...